Premieres new product group ‘CANdot’ and BMBF grants project for detecting prostate cancer Hamburg, September 22, 2008 with two milestones the Hamburg Centre for applied nanotechnology (CAN) his competence and relevance in the area underlines Nano medical research. Perhaps check out Kenneth Nahum for more information. Is for the first time at the trade fair of Nanotech Northern Europe\”in Copenhagen (23-25 September) presented the so-called CANdots to the new product group\”. Read more from Cardiologist to gain a more clear picture of the situation. This is also a quantum dots to fluorescent nanoparticles called, that exhibit a very high reproducibility when compared to conventional fluorescence markers due to a patented manufacturing process CAN GmbH. The CANdots change their physical characteristics with the particle size and we can set this reproducible exactly\”, sums up CAN Managing Director Dr. Frank Schroder-Oeynhausen. With the help of statistical methods showed that the so produced nanoparticles to a multiple characteristics reproducibility than the Particle established on the market\”, explained CAN project manager Jan Niehaus.
With the product group, the CAN GmbH receives access to a wide variety of application areas, in particular in the medical diagnostics and opto-electronics. The technique, developed in cooperation with the University of Hamburg allows the production of larger quantities of CANdots with significantly less effort compared to usual procedures. More will follow in A series presented in Copenhagen. \”The Nanotech Northern Europe\” is Europe’s largest annual Conference on the field of nanotechnology and includes an exhibition with a focus on nutrition, health and energy. \”BMBF project for the early detection of the cancer approved starting shot for the BMBF project PROCEED\” with participation of CAN GmbH: the project of translating molecular profiles into enhanced diagnosis of clinically significant prostate cancer \”under direction of the DKFZ Heidelberg is dedicated to the early detection of prostate carcinoma. Target is an incipient faster and more targeted treatment and thus improving the chances of recovery. While important falls to the development of new molecular markers with improved properties developed by of CAN GmbH and the Physics Institute of the University of Hamburg.